Internship

Quality Assurance Summer Intern

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$25 - $31Hourly

No H1B Sponsorship

San Carlos, CA, USA

Must work at the Redwood City office for the duration of the internship, no relocation available.

Category
QA & Testing
Quality Assurance
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Exceptional interpersonal skills and proven track record of teamwork, innovation, and initiative
  • Strong organizational skills
  • Capacity to quickly identify problems and create solutions
  • Highly effective in communicating in written, verbal, and presentation forms
  • Knowledge of Microsoft Office programs (i.e., Word, Excel, PowerPoint)
  • Must be able to complete at least 10 consecutive weeks between June and August and it is a full-time internship (40 hours per week)
  • Must be able to work at our Redwood City office for the duration of the internship, no relocation available
Responsibilities
  • Projects could include reviewing, organizing, and digesting complex information and documentation ranging from chemical manufacturing specifications to clinical study reports
  • Shadow QA team members in their work, including attending meetings ranging from simple weekly huddles to high-level strategy sessions
  • Contribute to Corcept’s preparation for regulatory inspections in support of new products
  • Deliver a department presentation at the end of the program
  • Participate as a member of the 2025 intern team group project that includes a company-wide presentation
Desired Qualifications
  • Pursuing an associate’s or bachelor's degree

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health conditions. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by excessive cortisol. Korlym was approved by the FDA in 2012 and is the first treatment specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-3%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
  • Advancements in drug delivery systems could enhance Corcept's product efficacy.
  • The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
  • Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
  • Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours